Darryl D. Dixon
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Darryl D. Dixon has a total of 116 co-authors. Here are the top co-authors by number of shared publications:
Bin Wang
Peloton Therapeutics, Inc. , 2330 Inwood Road, Suite 226 , Dallas , Texas 75235 , United States
3 shared publicationsEli M. Wallace
Peloton Therapeutics, Inc. , 2330 Inwood Road, Suite 226 , Dallas , Texas 75235 , United States
3 shared publicationsGuangzhou Han
Peloton Therapeutics, Inc. , 2330 Inwood Road, Suite 226 , Dallas , Texas 75235 , United States
3 shared publicationsHanbiao Yang
Peloton Therapeutics, Inc. , 2330 Inwood Road, Suite 226 , Dallas , Texas 75235 , United States
3 shared publicationsHeli Huang
Peloton Therapeutics, Inc. , 2330 Inwood Road, Suite 226 , Dallas , Texas 75235 , United States
3 shared publicationsJohn A. Josey
Peloton Therapeutics, Inc. , 2330 Inwood Road, Suite 226 , Dallas , Texas 75235 , United States
3 shared publications
Latest Publications
- 5 November 2024
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 28 (11) , 4099-4113
Early Process Development of an LPAR1 Antagonist, GS-2278
- 5 November 2024
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 28 (11) , 4099-4113
Early Process Development of an LPAR1 Antagonist, GS-2278
- 18 August 2022
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 26 (9) , 2694-2706
Process Development and Scale-Up of a Protease Inhibitor for the Treatment of HIV Featuring the Preparation of a Neopentyl Grignard Reagent and Development of a One-Pot Curtius Reaction
- 18 August 2022
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 26 (9) , 2694-2706
Process Development and Scale-Up of a Protease Inhibitor for the Treatment of HIV Featuring the Preparation of a Neopentyl Grignard Reagent and Development of a One-Pot Curtius Reaction
- 18 October 2019
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 23 (11) , 2482-2498
Rapid Development of a Commercial Process for Linrodostat, an Indoleamine 2,3-Dioxygenase (IDO) Inhibitor
- 18 October 2019
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 23 (11) , 2482-2498
Rapid Development of a Commercial Process for Linrodostat, an Indoleamine 2,3-Dioxygenase (IDO) Inhibitor
- Open Access
- 16 June 2019
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 23 (7) , 1378-1385
Revisiting the Cleavage of Evans Oxazolidinones with LiOH/H2O2
The use of LiOH/H2O2 for cleavage of Evans oxazolidinones is an essential but often overlooked part of using these ubiquitous chiral auxiliaries in synthetic routes. These conditions were disclosed in the literature more than 30 years ago and have found widespread use with little change. During studies focused on the synthesis of a drug candidate, we discovered the evolution of oxygen under the LiOH/H2O2 conditions for cleavage of an Evans auxiliary. We find this phenomenon to be general and tied to the fact that the initially formed peracid is not stable under the reaction conditions. The peracid is rapidly reduced by the excess H2O2 present in the reaction mixture, leading to the release of a stoichiometric amount of oxygen. This can present a significant risk for maintaining proper inertion in the presence of the flammable organic solvent, and we propose options for safely executing this chemistry at multikilogram scale.
- 16 June 2019
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 23 (7) , 1378-1385
Open AccessRevisiting the Cleavage of Evans Oxazolidinones with LiOH/H2O2
The use of LiOH/H2O2 for cleavage of Evans oxazolidinones is an essential but often overlooked part of using these ubiquitous chiral auxiliaries in synthetic routes. These conditions were disclosed in the literature more than 30 years ago and have found widespread use with little change. During studies focused on the synthesis of a drug candidate, we discovered the evolution of oxygen under the LiOH/H2O2 conditions for cleavage of an Evans auxiliary. We find this phenomenon to be general and tied to the fact that the initially formed peracid is not stable under the reaction conditions. The peracid is rapidly reduced by the excess H2O2 present in the reaction mixture, leading to the release of a stoichiometric amount of oxygen. This can present a significant risk for maintaining proper inertion in the presence of the flammable organic solvent, and we propose options for safely executing this chemistry at multikilogram scale.
- 5 October 2018
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 61 (21) , 9691-9721
Design and Activity of Specific Hypoxia-Inducible Factor-2α (HIF-2α) Inhibitors for the Treatment of Clear Cell Renal Cell Carcinoma: Discovery of Clinical Candidate (S)-3-((2,2-Difluoro-1-hydroxy-7-(methylsulfonyl)-2,3-dihydro-1H-inden-4-yl)oxy)-5-fluorobenzonitrile (PT2385)
HIF-2α, a member of the HIF family of transcription factors, is a key oncogenic driver in cancers such as clear cell renal cell carcinoma (ccRCC). A signature feature of these cancers is the over accumulation of HIF-2α protein, often by inactivation of the E3 ligase VHL (von Hippel-Lindau). Herein we disclose our structure based drug design (SBDD) approach that culminated in the identification of PT2385, the first HIF-2α antagonist to enter clinical trials. Highlights include the use of a putative n → π*Ar interaction to guide early analog design, the conformational restriction of an essential hydroxyl moiety, and the remarkable impact of fluorination near the hydroxyl group. Evaluation of select compounds from two structural classes in a sequence of PK/PD, efficacy, PK, and metabolite profiling identified 10i (PT2385, Luciferase EC50 = 27 nM) as the clinical candidate. Finally, a retrospective crystallographic analysis describes the structural perturbations necessary for efficient antagonism.
- 5 October 2018
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 61 (21) , 9691-9721
Design and Activity of Specific Hypoxia-Inducible Factor-2α (HIF-2α) Inhibitors for the Treatment of Clear Cell Renal Cell Carcinoma: Discovery of Clinical Candidate (S)-3-((2,2-Difluoro-1-hydroxy-7-(methylsulfonyl)-2,3-dihydro-1H-inden-4-yl)oxy)-5-fluorobenzonitrile (PT2385)
HIF-2α, a member of the HIF family of transcription factors, is a key oncogenic driver in cancers such as clear cell renal cell carcinoma (ccRCC). A signature feature of these cancers is the over accumulation of HIF-2α protein, often by inactivation of the E3 ligase VHL (von Hippel-Lindau). Herein we disclose our structure based drug design (SBDD) approach that culminated in the identification of PT2385, the first HIF-2α antagonist to enter clinical trials. Highlights include the use of a putative n → π*Ar interaction to guide early analog design, the conformational restriction of an essential hydroxyl moiety, and the remarkable impact of fluorination near the hydroxyl group. Evaluation of select compounds from two structural classes in a sequence of PK/PD, efficacy, PK, and metabolite profiling identified 10i (PT2385, Luciferase EC50 = 27 nM) as the clinical candidate. Finally, a retrospective crystallographic analysis describes the structural perturbations necessary for efficient antagonism.
- 1 August 2015
- Published by American Association for Cancer Research (AACR)
- Vol. 75 (15) , DDT01-01
Abstract DDT01-01: PT2385: First-in-class HIF-2α antagonist for the treatment of renal cell carcinoma
- 1 August 2015
- Published by American Association for Cancer Research (AACR)
- Vol. 75 (15) , DDT01-01
Abstract DDT01-01: PT2385: First-in-class HIF-2α antagonist for the treatment of renal cell carcinoma
- 1 August 2015
- Published by American Association for Cancer Research (AACR)
- Vol. 75, DDT01-01
Abstract 4011: Tumor evolution inferred by patterns of miRNA expression through the course of disease, therapy and recurrence in breast cancer
Hypoxia-inducible factors (HIFs), including HIF-1α and HIF-2α, are transcription factors that mediate cellular response to changes of oxygen supply. These proteins become stabilized under hypoxia and subsequently activate the expression of genes to facilitate cell survival and proliferation. HIF proteins are activated in many types of cancers due to the tumor hypoxic microenvironment and have been implicated in cancer initiation, progression and metastasis. The oncogenic role of HIF-2α is pertinent in clear cell renal carcinoma (ccRCC). In the majority of ccRCC tumors, the von Hippel-Lindau protein (VHL) that targets HIF-2α for degradation is inactivated, leading to the accumulation of HIF-2α and the activation of genes that drive kidney cancer tumorigenesis. We have identified small molecules that bind to the PAS-B domain of HIF-2α protein and block it's dimerization with ARNT (aryl hydrocarbon receptor nuclear translocator, HIF-1β), a prerequisite for its transcriptional activities. Specifically, we describe PT2385, a selective, orally active HIF-2α antagonist with potent anti-cancer activity in mouse models of ccRCC. PT2385 is currently under evaluation in Phase I clinical trials for the treatment of ccRCC.
- 1 August 2015
- Published by American Association for Cancer Research (AACR)
- Vol. 75, DDT01-01
Abstract 4011: Tumor evolution inferred by patterns of miRNA expression through the course of disease, therapy and recurrence in breast cancer
Hypoxia-inducible factors (HIFs), including HIF-1α and HIF-2α, are transcription factors that mediate cellular response to changes of oxygen supply. These proteins become stabilized under hypoxia and subsequently activate the expression of genes to facilitate cell survival and proliferation. HIF proteins are activated in many types of cancers due to the tumor hypoxic microenvironment and have been implicated in cancer initiation, progression and metastasis. The oncogenic role of HIF-2α is pertinent in clear cell renal carcinoma (ccRCC). In the majority of ccRCC tumors, the von Hippel-Lindau protein (VHL) that targets HIF-2α for degradation is inactivated, leading to the accumulation of HIF-2α and the activation of genes that drive kidney cancer tumorigenesis. We have identified small molecules that bind to the PAS-B domain of HIF-2α protein and block it's dimerization with ARNT (aryl hydrocarbon receptor nuclear translocator, HIF-1β), a prerequisite for its transcriptional activities. Specifically, we describe PT2385, a selective, orally active HIF-2α antagonist with potent anti-cancer activity in mouse models of ccRCC. PT2385 is currently under evaluation in Phase I clinical trials for the treatment of ccRCC.
- Open Access
- 14 June 2012
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 22 (16) , 5322-5325
C3-Heteroaroyl cannabinoids as photolabeling ligands for the CB2 cannabinoid receptor
- 14 June 2012
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 22 (16) , 5322-5325
Open AccessC3-Heteroaroyl cannabinoids as photolabeling ligands for the CB2 cannabinoid receptor